TOM-1Homo sapiens (Human)Cancer cell line
Also known as: TOM1
🤖 AI SummaryBased on 5 publications
Quick Overview
TOM-1 is a Ph+ leukemia cell line derived from a patient with Ph+ ALL.
Detailed Summary
TOM-1 is a Ph+ leukemia cell line derived from a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). It is characterized by the presence of the BCR-ABL fusion gene, which is a hallmark of Philadelphia chromosome-positive leukemias. The cell line exhibits the e1-a2 form of the BCR-ABL fusion, which is associated with the m-bcr breakpoint cluster region. TOM-1 has been used in research to study the molecular mechanisms of BCR-ABL fusion gene expression and its role in leukemogenesis. The cell line is also notable for its ability to express the p190 BCR-ABL protein, which is typically associated with the m-bcr translocation. Additionally, TOM-1 has been utilized in studies examining the effects of various treatments on Ph+ leukemia cells, including the response to tyrosine kinase inhibitors and other targeted therapies.
Research Applications
Study of BCR-ABL fusion gene expressionInvestigation of molecular mechanisms in Ph+ leukemiasEvaluation of tyrosine kinase inhibitors and targeted therapies
Key Characteristics
Ph+ (Philadelphia chromosome positive)BCR-ABL fusion genee1-a2 form of BCR-ABL fusionExpression of p190 BCR-ABL protein
Generated on 6/17/2025
Basic Information
| Database ID | CVCL_1895 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Bone marrow[UBERON:UBERON_0002371] |
Donor Information
| Age | 54 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Subtype Features | BCR-ABL1 |
Disease Information
| Disease | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) |
|---|---|
| Lineage | Lymphoid |
| Subtype | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1 |
| OncoTree Code | BLLBCRABL1 |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-001209_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene fusion | ABL1 | BCR-ABL1, BCR-ABL | - | BCR exon 1 fused to ABL1 exon 2 | PubMed=10576511, PubMed=10071072, PubMed=8751477 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
10,11
D13S317
8,11
D16S539
9,10
D18S51
13,15
D19S433
14,15
D21S11
31,33.2
D2S1338
18
D3S1358
16,17
D5S818
11,13
D7S820
10,12
D8S1179
13,14
FGA
19,23
Penta D
10,12
Penta E
11,18
TH01
7,9
TPOX
8,11
vWA
17,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
Leukemia 20:471-476(2006).
ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.";
Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.
Leuk. Res. 23:1055-1060(1999).
Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler H.G., MacLeod R.A.F., Uphoff C.C.
Leuk. Res. 23:207-215(1999).
Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
Janssen J.W.G., Drexler H.G.
Leukemia 11:441-447(1997).
Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.
Sakurada K., Kakinuma M., Miyazaki T.
Blood 69:990-998(1987).
Inhibitory effect of interleukin-4 on the in vitro growth of Ph1-positive acute lymphoblastic leukemia cells.
Minagawa T., Kurosawa M., Itaya T., Miyazaki T.
Blood 78:1574-1580(1991).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).